Clinical Podcasts Archive

Important:

Information contained in the following UpToDate Talk podcasts was current at the time of initial release. However, this content is not maintained or updated. For current clinical recommendations, please always consult UpToDate Online. Please note that we are no longer producing new clinical podcasts.

UpToDate faculty discuss important changes to the practice of medicine based in our clinical podcasts. Our contributors are recognized physician leaders in their fields and offer their expertise regarding each update and its impact on clinical practice.

Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View the UpToDate conflict of interest policy.

This is the complete archive for the UpToDate Clinical Talk Podcasts.

Pediatric behavior & celiac autoimmunity; Adjuvant capecitabine & HER2-negative breast cancer

Date Released: Aug 23 2017

In this episode, Dr. Ivor Hill discusses the psychological impact of celiac autoimmunity in children, and Dr. Daniel Hayes discusses adjuvant therapy with capecitabine for selected women with breast cancer.

Dr. HillDr. Ivor Hill is is Professor of Clinical Pediatrics at Ohio State University College of Medicine and Medical Director of the Celiac Disease Center at Nationwide Children's Hospital.
Dr. HayesDr. Daniel Hayes Professor of Medicine and the Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center. He is past president of the American Society of Clinical Oncology.

Segment on celiac disease autoimmunity (Dr. Ivor Hill):

  1. Smith LB, Lynch KF, Kurppa K, et al. Psychological Manifestations of Celiac Disease Autoimmunity in Young Children. Pediatrics 2017; 139.

Segment on adjuvant capecitabine (Dr. Daniel Hayes):

  1. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med 2017; 376:2147.

Ivor D Hill, MD Nothing to disclose

Daniel F Hayes, MD Grant/Research/Clinical Trial Support: Janssen R&D, LLC [Breast cancer (Abiraterone)]; Janssen R&D, LLC [Breast cancer (CellSearch)]; Puma Biotechnology, Inc. [Breast cancer (Neratinib)]; Pfizer [Breast cancer (Palbociclib)]; Astra Zeneca [Breast cancer (Circulating tumor cells)]; Eli Lilly and Company [Breast cancer]. Speaker's Bureau: Lilly Oncology (Breast cancer). Patent Holder: Immunicon Corporation [Inventor (05725638.0-1223-US2005008602)]; University of Michigan [Inventor (US 8,790,878 B2)]; University of Michigan [Inventor (US 8,951,484 B2)]. Equity Ownership/Stock Options: Oncimmune LLC [Stock]; Inbiomotion [Stock]. Other Financial Interest: Janssen R&D, LLC [Breast cancer (CellSearch)].

Edaravone for amyotrophic lateral sclerosis; Neonatal mortality in US planned home births

Date Released: Aug 9 2017

This episode features Dr. Jeremy Shefner, discussing the use of edaravone for the treatment of amyotrophic lateral sclerosis, and Dr. Charles Lockwood, discussing neonatal mortality in planned home births. Dr. Helen Hollingsworth hosts.

Dr. ShefnerDr. Jeremy Shefner is Professor and Chair of Neurology at the Barrow Neurological Institute, Professor of Neurology at the University of Arizona in Phoenix, and Clinical Professor of Neurology at Creighton University.
Dr. LockwoodDr. Charles Lockwood is Professor of Obstetrics and Gynecology at the University of South Florida, Dean of the Morsani College of Medicine and Senior Vice President of the University of South Florida Health.

Segment on edaravone for amyotrophic lateral sclerosis (Dr. Jeremy Shefner):

  1. Writing Group, Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017; 16:505.

Segment on neonatal mortality in US planned home births (Dr. Charles Lockwood):

  1. Grunebaum A, McCullough LB, Sapra KJ, et al. Planned home births: The need for additional contraindications. Am J Obstet Gynecol 2017; 216:401.e1.

Jeremy M Shefner, MD, PhD Grant/Research Support: Biogen Idec; Cytokinetics; Neuraltus [ALS]; Avanir [ALS (Nuedexta)]. Consultant/Advisory Boards: Biogen Idec; Cytokinetics; Ionis; Neuraltus; Mitsubishi Tanabe [ALS]; Edaravone [ALS (MT Pharma)].

Charles J Lockwood, MD, MHCM Consultant/Advisory Boards: Celula [Aneuploidy screening (No current products or drugs in the US)].

Buprenorphine for neonatal abstinence syndrome; Sublingual immunotherapy for house dust mite allergy

Date Released: Jul 26 2017

In this episode, Dr. Lauren Jansson discusses buprenorphine for neonatal abstinence syndrome, and Dr. Peter Creticos discusses a sublingual immunotherapy tablet for house dust mite allergies. Dr. Sadhna Vora hosts.

Dr. JanssonDr. Lauren Jansson is an Associate Professor of Pediatrics at the Johns Hopkins University School of Medicine and Director of Pediatrics at the Center for Addiction and Pregnancy.
Dr. CreticosDr. Peter Creticos is an Associate Professor of Medicine at the Johns Hopkins University School of Medicine.

Segment on buprenorphine for neonatal abstinence syndrome (Dr. Jansson):

  1. Kraft WK, Adeniyi-Jones SC, Chervoneva I, et al. Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome. N Engl J Med 2017; 376:2341.

Segment on sublingual immunotherapy tablet for house dust mite allergy (Dr. Creticos):

  1. Nolte H, Bernstein DI, Nelson HS, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol 2016; 138:1631.

Lauren M Jansson MD Nothing to disclose

Peter S Creticos, MD Grant/Research/Clinical Trial Support: Stallergenes-Greer [Immunotherapy (SLIT)]; Circassia [Immunotherapy (Peptides)]. Consultant/Advisory Boards: Circassia; Greer; ITI [Immunotherapy (SCIT; SLIT)]; Allakos [Cytokine antagonists]; ASIT [AIT].

Goal blood pressure in older adults; Dexamethasone and acute pharyngitis pain in adults

Date Released: Jul 12 2017

This episode features Dr. Brent Egan discussing the target blood pressure in older adults, and Dr. Mark Aronson discussing the use of dexamethasone for acute pharyngitis pain in adults. Dr. Nancy Sokol hosts.

Dr. NathanDr. Brent Egan is a Professor of Medicine at the University of South Carolina School of Medicine, and Chief Science Officer at the Care Coordination Institute.
Dr. AronsonDr. Mark Aronson is a Professor of Medicine at Harvard Medical School, Associate Chief of the Division of General Medicine and Primary Care and Vice Chair for Quality at the Beth Israel Deaconess Medical Center in Boston.

Segment on Goal blood pressure in older adults (Dr. Brent Egan):

  1. Bavishi C, Bangalore S, Messerli FH. Outcomes of Intensive Blood Pressure Lowering in Older Hypertensive Patients. J Am Coll Cardiol 2017; 69:486.

Segment on Dexamethasone for acute pharyngitis pain in adults (Dr. Mark Aronson):

  1. Hayward GN, Hay AD, Moore MV, et al. Effect of Oral Dexamethasone Without Immediate Antibiotics vs Placebo on Acute Sore Throat in Adults: A Randomized Clinical Trial. JAMA 2017; 317:1535.

Brent M Egan, MD Grant/Research/Clinical Trial Support: Boehringer [Diabetes (Empagliflozin)]. Speaker's Bureau: Medtronic [Hypertension (Renal artery denervation to lower blood pressure)]; Merck International [Hypertension, heart failure (Bisoprolol)]. Consultant/Advisory Boards: Valencia [Hypertension (Device-based treatment to lower blood pressure)]; Inside Edge Consulting [Clinical trials (Patient recruitment and retention)].

Mark D Aronson, MD Nothing to disclose

Pages